Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2705-2711

  Mulgaonkar, Aditi ^a   Venitz, Jürgen ^a   Gründemann, Dirk ^b   Sweet, Douglas H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ENOXACIN; FLEROXACIN; GATIFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; PEFLOXACIN; PRULIFLOXACIN; QUINOLONE DERIVATIVE; RUFLOXACIN; SPARFLOXACIN;

ARTICLE; BASOLATERAL MEMBRANE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG COMPETITION; DRUG POTENCY; DRUG TRANSPORT; INTESTINE CELL; KIDNEY PROXIMAL TUBULE; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTI-INFECTIVE AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; DRUG INTERACTIONS; ENTEROCYTES; FLUOROQUINOLONES; HEK293 CELLS; HEPATOCYTES; HUMANS; KIDNEY TUBULES, PROXIMAL; ORGANIC CATION TRANSPORT PROTEINS; ORGANIC CATION TRANSPORTER 1;

EID: 84877843706     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02289-12     Document Type: Article

References (45)

1. Appelbaum PC. 1999. Quinolone activity against anaerobes. Drugs 58: 60-64.
2. Hooper DC, Rubinstein E. 2003. Quinolone antimicrobial agents, 3rd ed. ASM Press, Washington, DC.
3. Scholar E. 2002. Fluoroquinolones: Past, present and future of a novel group of antibacterial agents. Am. J. Pharm. Educ. 66:164-171.
4. Lipsky BA, Baker CA. 1999. Fluoroquinolone toxicity profiles: A review focusing on newer agents. Clin. Infect. Dis. 28:352-364.
5. Wiles J, Bradbury B, Pucci M. 2010. New quinolone antibiotics: A survey of the literature from 2005 to 2010. Expert Opin. Ther. Pat. 20:1295-1319.
6. Mulgaonkar A, Venitz J, Sweet DH. 2012. Fluoroquinolone disposition: Identification of the contribution of renal secretory and reabsorptive drug transporters. Expert Opin. Drug Metab. Toxicol. 8:553-569.
7. Sweet DH. 2010. Renal organic cation and anion transport: From physiology to genes, p 23-53. In McQueenCA(ed), Comprehensive toxicology, 2nd ed, vol 7. Elsevier Ltd, Oxford, United Kingdom.
8. Neu HC. 1992. Quinolone antimicrobial agents. Annu. Rev. Med. 43: 465-486.
9. Oliphant CM, Green GM. 2002. Quinolones: A comprehensive review. Am. Fam. Physician 65:455-464.
10. Koepsell H, Lips K, Volk C. 2007. Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 24:1227-1251.
11. Tahara H, Kusuhara H, Endou H, Koepsell H, Imaoka T, Fuse E, Sugiyama Y. 2005. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J. Pharmacol. Exp. Ther. 315:337-345.
12. Umehara KI, Iwatsubo T, Noguchi K, Kamimura H. 2007. Functional involvement of organic cation transporter1 (OCT1/oct1) in the hepatic uptake of organic cations in humans and rats. Xenobiotica 37:818-831.
13. Gaitonde M, Mendes P, House ESA, Lehr KH. 1995. Abstr. 35th Intersci. Conf. Antimicrob. Agents Chemother., abstr A-41.
14. Misiak PM, Eldon MA, Toothaker RD, Sedman AJ. 1993. Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin. J. Clin. Pharmacol. 33:53-56.
15. Sorgel F, Kinzig M. 1993. Pharmacokinetics of gyrase inhibitors, part 2: Renal and hepatic elimination pathways and drug interactions. Am. J. Med. 94:56S-69S.
16. Bauer LA, Black DJ, Lill JS, Garrison J, Raisys VA, Hooton TM. 2005. Levofloxacin and ciprofloxacin decrease procainamide and Nacetylprocainamide renal clearances. Antimicrob. Agents Chemother. 49: 1649-1651.
17. Hasannejad H, Takeda M, Narikawa S, Huang XL, Enomoto A, Taki K, Niwa T, Jung SH, Onozato ML, Tojo A, Endou H. 2004. Human organic cation transporter 3 mediates the transport of antiarrhythmic drugs. Eur. J. Pharmacol. 499:45-51.
18. Martin DE, Shen J, Griener J, Raasch R, Patterson JH, Cascio W. 1996. Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide. J. Clin. Pharmacol. 36:85-91.
19. Masago M, Takaai M, Sakata J, Horie A, Ito T, Ishida K, Taguchi M, Hashimoto Y. 2010. Membrane transport mechanisms of quinidine and procainamide in renal LLC-PK1 and intestinal LS180 cells. Biol. Pharm. Bull. 33:1407-1412.
20. Minematsu T, Iwai M, Umehara K, Usui T, Kamimura H. 2010. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)-and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3- (pyrazin-2-ylmethyl)-4,9-dihydro-1h-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab. Dispos. 38:1-4.
21. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V. 2000. Structure, function, and regional distribution of the organic cation transporter Oct3 in the kidney. Am. J. Physiol. Renal Physiol. 279:F449-F458.
22. Okuda M, Kimura N, Inui K. 2006. Interactions of fluoroquinolone antibacterials, DX-619 and levofloxacin, with creatinine transport by renal organic cation transporter hOCT2. Drug Metab. Pharmacokinet. 21:432-436.
23. Imamura Y, Murayama N, Okudaira N, Kurihara A, Okazaki O, Izumi T, Inoue K, Yuasa H, Kusuhara H, Sugiyama Y. 2011. Prediction of fluoroquinolone-induced elevation in serum creatinine levels: A case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin. Pharmacol. Ther. 89:81-88.
24. Grundemann D, Hahne C, Berkels R, Schomig E. 2003. Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2). J. Pharmacol. Exp. Ther. 304:810-817.
25. Grundemann D, Schechinger B, Rappold GA, Schomig E. 1998. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat. Neurosci. 1:349-351.
26. VanWert AL, Srimaroeng C, Sweet DH. 2008. Organic anion transporter 3 (Oat3/Slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. Mol. Pharmacol. 74:122-131.
27. Wang L, Sweet DH. 2012. Active hydrophilic components of the medicinal herb salvia miltiorrhiza (danshen) potently inhibit organic anion transporters 1 (Slc22a6) and 3 (Slc22a8). Evid. Based Complement. Alternat. Med. 2012:872458. doi:10.1155/2012/872458.
28. Martel F, Keating E, Calhau C, Grundemann D, Schomig E, Azevedo I. 2001. Regulation of human extraneuronal monoamine transporter (hEMT) expressed in HEK293 cells by intracellular second messenger systems. Naunyn Schmiedebergs Arch. Pharmacol. 364:487-495.
29. Copeland RA. 2000. Enzymes: A practical introduction to structure, mechanism, and data analysis, 2nd ed, p 266-303. Wiley-VCH, Inc, New York, NY.
30. Gajjar D, LaCreta F, Uderman H, Kollia G, Duncan G, Birkhofer M, Grasela D. 2000. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy 20:49S-58S. doi:10.1592/phco.20.8.49S.35186.
31. Nakashima M, Uematsu T, Kosuge K, Kusajima H, Ooie T, Masuda Y, Ishida R, Uchida H. 1995. Single-and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob. Agents Chemother. 39:2635-2640.
32. Stass H, Kubitza D, Möller J, Delesen H. 2005. Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400mg single dose to healthy males. Br. J. Clin. Pharmacol. 59:536-541.
33. Stass H, Sachse R. 2001. Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers. Clin. Pharmacokinet. 40:71-76.
34. Montay G. 1996. Pharmacokinetics of sparfloxacin in healthy volunteers and patients: A review. J. Antimicrob. Chemother. 37:27-39.
35. Montay G, Bruno R, Vergniol JC, Ebmeier M, Le Roux Y, Guimart C, Frydman A, Chassard D, Thebault JJ. 1994. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. J. Clin. Pharmacol. 34:1071-1076.
36. Hirano T, Yasuda S, Osaka Y, Kobayashi M, Itagaki S, Iseki K. 2006. Mechanism of the inhibitory effect of zwitterionic drugs (levofloxacin and grepafloxacin) on carnitine transporter (OCTN2) in Caco-2 cells. Biochim. Biophys. Acta 1758:1743-1750.
37. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A. 1999. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J. Pharmacol. Exp. Ther. 289:768-773.
38. Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K. 2007. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H-organic cation antiporters. Biochem. Pharmacol. 74: 359-371.
39. Karbach U, Kricke J, Meyer-Wentrup F, Gorboulev V, Volk C, Loffing-Cueni D, Kaissling B, Bachmann S, Koepsell H. 2000. Localization of organic cation transporters Oct1 and Oct2 in rat kidney. Am. J. Physiol. Renal Physiol. 279:F679-F687.
40. Siefert HM, Domdey-Bette A, Henninger K, Hucke F, Kohlsdorfer C, Stass HH. 1999. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: A comparison in humans and other mammalian species. J. Antimicrob. Chemother. 43:69-76.
41. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. 2010. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9:215-236.
42. Kerb R. 2006. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 234:4-33.
43. Meyer UA. 2000. Pharmacogenetics and adverse drug reactions. Lancet 356:1667-1671.
44. Pedersen JM, Matsson P, Bergstrom CA, Norinder U, Hoogstraate J, Artursson P. 2008. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrugresistance associated protein 2 (MRP2; ABCC2). J. Med. Chem. 51: 3275-3287.
45. Kindla J, Muller F, Mieth M, Fromm MF, Konig J. 2011. Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1-and OATP1B3-mediated drug transport. Drug Metab. Dispos. 39:1047-1053.